BiVACOR® is a clinical-stage medical device company developing the BiVACOR Total Artificial Heart (TAH), designed to address the global unmet need of end-stage HF patients by providing a next-generation life-extending solution.
The BiVACOR TAH is designed to replace the complete function of the native heart. BiVACOR is headquartered in Huntington Beach, CA, with additional offices in Houston, TX, and on the Gold Coast, Australia.
BiVACOR was founded in 2008 by a team of internationally renowned biomedical engineers and cardiac surgeons, including Chief Technical Officer Daniel Timms, Ph.D. and Chief Medical Officer, William Cohn MD.
Today, BiVACOR has a robust collaborative network extending nationally and internationally, boasting a team of world-class engineers, medical specialists, and business executives fervent to advance this ground-breaking technology and focus on “Replacing Hearts and Restoring Lives.”
See the BiVACOR website for more details.